Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Monique C. Minnema, MD PhD, Sanne de Haart, MD, Tuna Mutis, MD PhD, Marco Koudijs, PhD, Marja van Blokland, Henk Lokhorst, MD PhD, Roel de Weger, MD PhD, Stefan Willems, MD PhD

Blood (2015) 126 (23): 4174.

https://doi.org/10.1182/blood.V126.23.4174.4174

Published: 2015

Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Pieter Sonneveld, MD, Emilie Asselbergs, Sonja Zweegman, MD, PhD, Bronno Van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Henk Lokhorst, MD, PhD

Blood (2012) 120 (21): 333.

https://doi.org/10.1182/blood.V120.21.333.333

Published: 2012

Journal Articles

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 1834.

https://doi.org/10.1182/blood.V120.21.1834.1834

Published: 2012

Journal Articles

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Pieter Sonneveld, MD, Okke de Weerdt, Mark-David Levin, Wendimagegn Ghidey, Edo Vellenga, Saskia K Klein, Jeanette Doorduyn, Marie José Kersten, P.W. Wijermans, MD, PhD, Henk Lokhorst, MD

Blood (2012) 120 (21): 1853.

https://doi.org/10.1182/blood.V120.21.1853.1853

Published: 2012

Journal Articles

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

Annemiek Broyl, MD, Rowan Kuiper, BSc, Mark van Duin, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, Uta Bertsch, MD, Sonja Zweegman, MD, PhD, Arjan Buijs, PhD, Dirk Hose, MD, PhD, Henk Lokhorst, MD, PhD, Hartmut Goldschmidt, MD, PhD, Pieter Sonneveld, MD

Blood (2012) 120 (21): 3973.

https://doi.org/10.1182/blood.V120.21.3973.3973

Published: 2012

Journal Articles

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Torben Plesner, MD, Henk Lokhorst, MD, PhD, Peter Gimsing, MD, PhD, Hareth Nahi, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2012) 120 (21): 73.

https://doi.org/10.1182/blood.V120.21.73.73

Published: 2012

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Blood (2012) 120 (21): 749.

https://doi.org/10.1182/blood.V120.21.749.749

Published: 2012

Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD

Blood (2012) 120 (21): 4988.

https://doi.org/10.1182/blood.V120.21.4988.4988

Published: 2012

Journal Articles

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Peter Gimsing, MD, DMSci, Assoc. Prof., Torben Plesner, MD, Hareth Nahi, Henk Lokhorst, MD, PhD, Marie-Louise Valentin, MD, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2011) 118 (21): 1873.

https://doi.org/10.1182/blood.V118.21.1873.1873

Published: 2011

Journal Articles

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients

Blood (2011) 118 (21): 996.

https://doi.org/10.1182/blood.V118.21.996.996

Published: 2011

Journal Articles

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

Richard W Groen, Frans M Hofhuis, Linda Aalders, Berris van Kessel, Michel de Weers, PhD, Tuna Mutis, MD, PhD, Henk Lokhorst, MD, PhD, Anton C Martens, PhD

Blood (2010) 116 (21): 981.

https://doi.org/10.1182/blood.V116.21.981.981

Published: 2010

Journal Articles

Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study

Monique C. Minnema, MD, PhD, Evelien Kneppers, MD, Ronnie van Der Holt, PhD, Marie Jose Kersten, MD, PhD, Sonja Zweegman, MD, PhD, Ellen Meijer, MD, PhD, Edo Vellenga, MD, PhD, Tuna Mutis, MD, PhD, Petra Cornelisse, Henk Lokhorst, MD, PhD

Blood (2010) 116 (21): 3502.

https://doi.org/10.1182/blood.V116.21.3502.3502

Published: 2010

Journal Articles

Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib

Annemiek Broyl, MD, Sophie Corthals, Joost L.M. Jongen, MD, PhD, Bronno van der Holt, PhD, Rowan Kuiper, Yvonne de Knegt, Laila el Jarari, Uta Bertsch, MD, PhD, Henk Lokhorst, MD, PhD, Brian GM Durie, MD, PhD, Hartmut Goldschmidt, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2010) 116 (21): 304.

https://doi.org/10.1182/blood.V116.21.304.304

Published: 2010

Journal Articles

Improving Tumor Immunotherapy by Using Distinct Subpopulations of the γδT Cell Repertoire with High Anti-Tumor Reactivity.

Suzanne van Dorp, MD, Samantha Hol, Victoria Marcu-Malina, PhD, Nicole Thuss, Henk Lokhorst, MD, PhD, Juergen Kuball, MD, PhD

Blood (2009) 114 (22): 4504.

https://doi.org/10.1182/blood.V114.22.4504.4504

Published: 2009

Journal Articles

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

Richard W.J. Groen, Frans M. Hofhuis, Henk-Jan Prins, Henk Rozemuller, PhD, Berris van Kessel, Michel de Weers, PhD, Henk Lokhorst, MD, PhD, Anton C.M. Martens, PhD

Blood (2009) 114 (22): 1847.

https://doi.org/10.1182/blood.V114.22.1847.1847

Published: 2009

Journal Articles

B- Cell Depletion as Therapy for Steroid Refractory Chronic Gvhd Is Most Effective for Sclerosis of the Skin.

Suzanne van Dorp, MD, Henk Lokhorst, MD, PhD, Eefke Petersen, MD, PhD, Monique C. Minnema, MD, PhD, Lambert F. Span, MD, PhD, Saskia Ebeling, PhD, Marijke van Dijk, MD, PhD, Ellen Meijer, MD, PhD, Juergen Kuball, MD, PhD

Blood (2009) 114 (22): 2232.

https://doi.org/10.1182/blood.V114.22.2232.2232

Published: 2009

Journal Articles

Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study

Henk Lokhorst, MD, PhD, Pieter Sonneveld, MD, PhD, Bronno van der Holt, PhD, Marinus van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Sonja Zweegman, MD, PhD, Monique C. Minnema, MD, PhD, Mark Zijlmans, MD, PhD

Blood (2008) 112 (11): 461.

https://doi.org/10.1182/blood.V112.11.461.461

Published: 2008

NARROW

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study

Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib

Improving Tumor Immunotherapy by Using Distinct Subpopulations of the γδT Cell Repertoire with High Anti-Tumor Reactivity.

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

B- Cell Depletion as Therapy for Steroid Refractory Chronic Gvhd Is Most Effective for Sclerosis of the Skin.

Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only